Tag Archive for: blood-brain barrier delivery

Credit: Victor via Unsplash+
Neurodegenerative Disorders

Novartis ends BioArctic brain-delivery deal worth up to $802M

Swedish biotech BioArctic has lost a partnership with Swiss drugmaker Novartis to develop a potential treatment for neurodegenerative diseases using its BrainTransporter technology. The termination eliminates the prospect of up to $772 million (€691 million) in additional payments, although BioArctic retains the $30 million (€27 million) upfront payment.

Read more
MoA of BioArtic's brain transporter technology that improved antibody uptake 70-fold in preclinical testsBioArctic AB
Neurodegeneration

Novartis secures US$30m+ licence option from BioArctic

Following the commercial launch of BioArctic AB’s Alzheimer’s antibody lecanemab, the Swedish company has announced a new deal: it will receive an upfront payment of US$30m, granting the Swiss company access to BioArctic’s BrainTransporter platform to transport therapeutics for neurodegeneration across the blood-brain barrier

Read more